Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present RenovaCare, Inc. (OTC: RCAR).

Full DD Report for RCAR

You must become a subscriber to view this report.



Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-132.052.062.061.946,460
2018-12-122.101.992.101.9710,807
2018-12-111.992.0652.201.996,371
2018-12-102.002.002.062.006,810
2018-12-071.992.002.231.9113,702

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-134,6706,46072.2910Short
2018-12-122,11410,80719.5614Cover
2018-12-113,2386,37150.8240Short
2018-12-101,6956,81024.8899Cover
2018-12-075,39013,70239.3373Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on RCAR.


About RenovaCare, Inc. (OTC: RCAR)

Logo for RenovaCare, Inc. (OTC: RCAR)

RenovaCare, Inc. is a biotechnology company focused on developing first of their kind autologous self donated stem cell therapies for the regeneration of human organs. Our initial products under development target the body s largest organ, the skin. Our flagship technology, the CellMist System, uses our proprietary SkinGun to spray a liquid suspension of a patient s stem cells and the CellMist Solution onto wounds. In investigative clinical use in the United States, SkinGun treatments have shown the potential to naturally and rapidly heal burns and other serious wounds. We are developing our CellMist System as a promising new alternative for patients suffering from burns, chronic and acute wounds, and scars.

 

Contact Information

 

 

Current Management

  • Thomas Bold / President, CEO
    • Since Mr. Bold has served as Business Consultant and Economic Advisor to StemCell Systems, GmbH. S Advisor, he serves on the steering committee of a multinational research project sponsored by the European Commission. From through Mr. Bold served as the CEO of StemCell Systems. As CEO, Mr. Bold managed several national and international R amp D projects. Mr. Bold has years of professional business experience in the field of medical biotechnology device manufacturing, stem cell culture technology platform development and regenerative medicine research project management and product development. Mr. Bold cofounded several startup companies in Germany. He initiated and managed successful business/R amp D collaborations between many company and university partners and has been involved in successful patent application processes and IP portfolio management. Mr. Bold has assisted in securing millions of dollars of funding from local and national German research organizations and the European Commission and managed national and international life science R amp D projects for Hybrid Organ GmbH, StemCell Systems GmbH and the Charit Medical Faculty of the Berlin Universities, Germany. Mr. Bold received his Bachelor s in Business Management from the University of Cologne, Germany and DiplomKaufmann Masters degree in Business Management, Economic Journalism and American Economy from the Freie Universit t Berlin.
  • Patsy Trisler / VP, Regulatory Affairs
    • For over years Ms. Trisler has provided strategic regulatory guidance and clinical compliance consulting services to medical device companies, including advising on nonclinical and clinical testing requirements for a variety of product types preparing FDA submissions facilitating FDA meetings training on compliance with GCPs amp FDA regulatory requirements. Ms. Trisler has been a regulatory consultant since and has held senior level positions where she provided consulting services for pharmaceutical, biotechnology and medical device clients and was most recently an independent consultant for a number of clients within the medical products industry. Prior to that Ms. Trisler served for nearly seven years at the FDA as a scientific reviewer and special assistant to the Director of the Office of Device Evaluation. She began her career as a biologist at the National Cancer Institute NCI . Ms. Trisler received her B.S. in biology and psychology from American University in Washington, DC, and her juris doctorate from the Potomac School of Law/Antioch Law School in Washington, DC. Ms. Trisler is regulatory affairs certified RAC and a member of several professional groups, including the Association of Clinical Research Professionals, and Regulatory Affairs Professional Society. Ms. Rosen was appointed to serve as our VicePresident, Regulatory amp Clinical Affairs due to her extensive regulatory guidance and clinical compliance experience.
  • Thomas Bold / Director
    • Since Mr. Bold has served as Business Consultant and Economic Advisor to StemCell Systems, GmbH. S Advisor, he serves on the steering committee of a multinational research project sponsored by the European Commission. From through Mr. Bold served as the CEO of StemCell Systems. As CEO, Mr. Bold managed several national and international R amp D projects. Mr. Bold has years of professional business experience in the field of medical biotechnology device manufacturing, stem cell culture technology platform development and regenerative medicine research project management and product development. Mr. Bold cofounded several startup companies in Germany. He initiated and managed successful business/R amp D collaborations between many company and university partners and has been involved in successful patent application processes and IP portfolio management. Mr. Bold has assisted in securing millions of dollars of funding from local and national German research organizations and the European Commission and managed national and international life science R amp D projects for Hybrid Organ GmbH, StemCell Systems GmbH and the Charit Medical Faculty of the Berlin Universities, Germany. Mr. Bold received his Bachelor s in Business Management from the University of Cologne, Germany and DiplomKaufmann Masters degree in Business Management, Economic Journalism and American Economy from the Freie Universit t Berlin.
  • Kenneth Kirkland / Director
    • From August through July , Dr. Kirkland worked as an Executive Director at Iowa State University and most recently served as the University ss Executive Director of the Research Foundation and Director of the Office of Intellectual Property and Technology Transfer. While there, he was successful in increasing the licensing of the University s technologies to companies to achieve number one ranking among U.S. universities in the number of licenses executed. Dr. Kirkland also spearheaded successful litigation against infringers of the Research Foundation s intellectual property resulting in total settlements of million. Dr. Kirkland completed his undergraduate studies in the U.K., and obtained his M.S. and Ph.D. degrees in Agronomic Crop Science from Oregon State University.
  • Joseph Sierchio / Director
    • Mr. Sierchio earned his J.D. at Cornell University Law School in , and a B.A., with Highest Distinction in Economics from Rutgers College at Rutgers University in . Mr. Sierchio has been engaged in the practice of law as a member of Satterlee Stephens LLP, our counsel, since September . Prior to that, Mr. Sierchio was engaged in the practice of law as a member of Sierchio amp Partners, LLP from May through September . Since , Mr. Sierchio has continuously practiced corporate and securities law in New York City, representing domestic and foreign corporations, investors, brokerage firms, entrepreneurs, and public and private companies in the U.S., Canada, United Kingdom, Germany, Italy, Switzerland, Australia, and Hong Kong. Mr. Sierchio is admitted in all New York state courts and federal courts in the Eastern, Northern, and Southern Districts of the State of New York as well as the federal Court of Appeals for the Second Circuit. Mr. Sierchio is also a director of SolarWindow Technologies Inc., which is engaged in the research and development of renewable energy technology. Mr. Sierchio was invited to join the Board due to his experience representing corporations public and private and individuals in numerous and various organizational, compliance, administrative, governance, finance equity and debt private and public offerings , regulatory and legal matters.

Current Share Structure

  • Market Cap: $412,708,166 - 03/16/2018
  • Authorized: 500,000,000 - 06/29/2017
  • Issue and Outstanding: 76,840,522 - 03/06/2018
  • Float: 25,326,835 - 01/04/2018

 


Recent Filings from (OTC: RCAR)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 14 2018
Prospectus filed under Rule 424(b)(4)
Filing Type: 424B4Filing Source: edgar
Filing Date: April, 25 2018
Post-effective amendment to an S-Type filing
Filing Type: POS AMFiling Source: edgar
Filing Date: April, 18 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: April, 17 2018
Amendment to general form for registration of securities under the Securities Act of 1933
Filing Type: S-1/AFiling Source: edgar
Filing Date: April, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 26 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 13 2018
Notice from the SEC of registration effectiveness
Filing Type: EFFECTFiling Source: edgar
Filing Date: March, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 27 2018
Post-effective amendment to an S-Type filing
Filing Type: POS AMFiling Source: edgar
Filing Date: February, 20 2018

 

 


Daily Technical Chart for (OTC: RCAR)

Daily Technical Chart for (OTC: RCAR)


Stay tuned for daily updates and more on (OTC: RCAR)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: RCAR)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in RCAR is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of RCAR and does not buy, sell, or trade any shares of RCAR. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/